|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 8. Metamorphosis is inhibited by treatment with methimazol (a goiterogen), and
resumes with subsequent thyroid hormone treatment. Inhibition of endogenous
thyroid hormone production with methimazol (0.1 mol l-1) for 4
weeks inhibits eye migration, frontal bone deformation, supraorbital bar (SB)
degradation, and pectoral fin remodeling, but not ossification or formation of
right lateral ethmoid and parietal barb bones (A,B'). Subsequent T3
treatment (100 nmol l-1, 1 week) results in partial eye migration,
SB degradation, and remodeling of pectoral fins to the adult form, but no
further frontal bone deformation. (A,A',C,C') Bone (Alizarin Red)
and cartilage (Alcian Blue) processed tissues; (B,B',D,D')
calcein-stained bone. Boxed regions denote pectoral fin locations; for higher
magnifications see Fig. 10.
Intact and resorbed right SB (closed and open red arrows, respectively);
frontal bones (white arrows); lateral ethmoid (white arrowheads); parietal
barb (black arrowheads). Bars, 1.0 mm (A,C); 0.2 mm
(A',B,B',C'D,D').
|
